1. Medicare Part D: CMS should monitor effects of rebates on drug coverage and spending : testimony before the Subcommittee on Health, Committee on Energy and Commerce, House of Representatives Publication: Washington, DC : United States Government Accountability Office, September 19, 2023 Subject(s): Government RegulationLegislation, MedicalMedicare Part D -- economicsMedicare Part D -- organization & administrationPrescription Drugs -- economicsUnited States
